Aeon Biopharma
web2AEON Biopharma is an American clinical stage biotechnology company developing ABP450, a botulin...
About
AEON Biopharma is an American clinical stage biotechnology company developing ABP450, a botulinum toxin product intended for therapeutic use through a proposed biosimilar development pathway. The company is investigating whether its formulation can meet regulatory requirements for comparison with Botox, an established treatment used across several medical indications. Its development strategy focuses on therapeutic applications rather than cosmetic procedures, with the objective of expanding treatment options for patients and healthcare providers. AEON works with regulatory authorities on the clinical and scientific evidence required for its proposed biosimilar. ABP450 remains a development product rather than an approved therapeutic biosimilar.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Aeon Biopharma profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy